The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

In 2024, drug makers lowered the cost of dozens of common medications to avoid penalties imposed by the American Rescue Plan, Katie Thomas of ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

A law signed in 2023 caps out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors beginning Jan. 1.

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short ... to discontinue production of certain insulin presentations and more dated delivery technologies ...

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

This move is a milestone, he noted, as for the first time insulin is being produced as pens inside Egypt, after it was previously produced only in the form of injections. This achievement reflects ...